Document Type : Original Article
Authors
- Fatemeh Ghoroubi 1
- Mandana Alamdari Mahd 2
- Azim Mehrvar 3
- Bibi Shahin Shamsian 4
- Sara Tavassoli-Hojjati 5
1 Dentist, School of Dentistry, Islamic Azad University of Tehran, Tehran, Iran.
2 Postgraduate Student, Dept. of Pediatrics, School of Dentistry, Islamic Azad University of Tehran, Tehran, Iran.
3 Mahak Hematology Oncology Research Center (Mahak-HORC), Mahak Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
4 Pediatric Congenital Disorders Research Center, Mofid Children Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
5 Dept. of Pediatric Dentistry, Faculty of Dentistry, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Abstract
Statement of the Problem: Chemotherapy-induced mucositis is the most common complication during cancer treatment. This complication can lead to pain, increased risk of infection and malnutrition. Therefore, it is important to find a solution to reduce the severity and duration of side effects.
Purpose: This study aimed to assess the efficacy of Mucosamin spray as an adjunct for prevention of oral mucositis in children under chemotherapy.
Materials and Method: This parallel-design clinical trial evaluated 48 patients aged 5 to 15 years with leukemia and lymphoma presenting to the Hematology Department of Mofid and Mahak Hospitals. The patients were randomly divided into two groups (n=24). Before starting chemotherapy, all patients received oral hygiene instructions (toothbrushing without flossing). Patients in both groups were requested to use a mouthwash composed of nystatin, aluminum-magnesium hydroxide suspension (aluminum MgS), and diphenhydramine for 1 min every morning on a daily basis starting the day before treatment. Patients in the intervention group were also requested to spray their entire oral mucosa with Mucosamin spray 3 times a day in addition to using the mouthwash. Patients were requested to refrain from eating and drinking for 1h after spraying. The patients were clinically examined by a senior dental student once every other day for 20 days regarding the occurrence, severity, and duration of oral mucositis. Data were analyzed using the Chi-square and Mann-Whitney tests, Kaplan-Meier survival analysis, and log rank test.
Results: No significant difference was noted between the two groups in the incidence, severity, or time of development of mucositis (p> 0.05). The 7-day non-recovery percentage was 72.7% (SE= 13.4) and 25.0% (SE= 15.3) in the control and test groups, respectively, indicating shorter duration (faster healing) of mucositis in the intervention group (p= 0.01).
Conclusion: Within the limitations of this study, it seems that prophylactic application of Mucosamin spray can shorten the course of oral mucositis, in case of its occurrence.
Highlights
Sara Tavassoli Hojati Google Scholar
Keywords
- Harris DJ. Cancer treatment-induced mucositis pain: strategies for assessment and management. Ther Clin Risk Manag. 2006; 2: 251-258.
- Cirillo N, Vicidomini A, McCullough M, Gambardella A, Hassona Y, Prime SS, et al. A hyaluronic acid-based compound inhibits fibroblast senescence induced by oxidative stress in vitro and prevents oral mucositis in vivo. J Cell Physiol. 2015; 230: 1421-1429.
- Raber-Durlacher JE, Weijl NI, Abu*Saris M, de*Koning B, Zwinderman AH, Osanto S. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer. 2000; 8: 366-371.
- Jadaud E, Bensadoun R. Low-level laser therapy: a standard of supportive care for cancer therapy-induced oral mucositis in head and neck cancer patients? Laser Ther. 2012; 21: 297-303.
- Alvarino-Martin C, Sarrion-Perez MG. Prevention and treatment of oral mucositis in patients receiving chemotherapy. J Clin Exp Dent. 2014; 6: e74-80.
- Mendoza G, Alvarez AI, Pulido MM, Molina AJ, Merino G, Real R, et al. Inhibitory effects of different antioxidants on hyaluronan depolymerization. Carbohydr Res. 2007; 342: 96-102.
- Lee JH, Jung JY, Bang D. The efficacy of topical 0.2% hyaluronic acid gel on recurrent oral ulcers: comparison between recurrent aphthous ulcers and the oral ulcers of Behcet's disease. J Eur Acad Dermatol Venereol. 2008; 22: 590-595.
- Colella G, Cannavale R, Vicidomini A, Rinaldi G, Compilato D, Campisi G. Efficacy of a spray compound containing a pool of collagen precursor synthetic aminoacids (l-proline, l-leucine, l-lysine and glycine) combined with sodium hyaluronate to manage chemo/radiotherapy-induced oral mucositis: preliminary data of an open trial. Int J Immunopathol Pharmacol. 2010; 23: 143-151.
- Bardellini E, Amadori F, Schumacher RF, D'Ippolito C, Porta F, Majorana A. Efficacy of a Solution Composed by Verbascoside, Polyvinylpyrrolidone (PVP) and Sodium Hyaluronate in the Treatment of Chemotherapy-induced Oral Mucositis in Children with Acute Lymphoblastic Leukemia. J Pediatr Hematol Oncol. 2016; 38: 559-562.
- Ruggiero T, Pol R, Camisassa D, Arata V, Martino I, Giaccone L, et al. Use of sodium hyaluronate and synthetic amino acid precursors of collagen for the symptomatic treatment of mucositis in patients undergoing haematopoietic stem cell transplants. J Biol Regul Homeost Agents. 2016; 30: 889-894.
- Ruggiero T, Pol R, Camisassa D, Simiele S, Giaccone L, Carossa S. Treatment of symptomatic oral mucositis with sodium hyaluronate and synthetic amino acid precursors of collagen in patients undergoing haematopoietic stem cell transplantation. J Biol Regul Homeost Agents. 2018; 32: 737-743.
- Meyer-Hamme G, Beckmann K, Radtke J, Efferth T, Greten HJ, Rostock M, et al. A survey of chinese medicinal herbal treatment for chemotherapy-induced oral mucositis. Evid Based Complement Alternat Med. 2013; 2013: 284959.
- Longo D. Harrison’s Hematology and Oncology, McGraw-Hill Education. 3th ed. McGraw-Hill Education: New York; 2017.
- Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004; 100: 1995-2025.
- Trotti A, Bellm LA, Epstein JB, Frame D, Fuchs HJ, Gwede CK, et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol. 2003; 66: 253-262.
- Barber C, Powell R, Ellis A, Hewett J. Comparing pain control and ability to eat and drink with standard therapy vs Gelclair: a preliminary, double centre, randomised controlled trial on patients with radiotherapy-induced oral mucositis. Support Care Cancer. 2007; 15: 427-440.
- Nasrollahi H, Khaki S, Ansari M, Ahmadloo N, Khanjani N, Hamedi SH, et al. Evaluation of mucosamin effect on treating radiation induced oral mucositis during and after radiotherapy amongst patients with oral cavity squamous cell carcinoma. Asian Pacific J Cancer Prevention (APJCP). 2021; 22: 3711.
- Shahrabi M, Solduzian M, Babaie MH, Mousavi SA, Goodarzi N, Ravari NS, et al. The effects of a combination oral spray (Mucosamin®) for the prevention of oral mucositis in pediatric patients undergoing hematopoietic stem cell transplantation: a double blind randomized clinical trial. Supportive Care in Cancer. 2022; 30: 7963-7972.
- Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ. Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol. 2014; 2: 337-340.
)